FGFR3 GENE SHORT VARIANTS

Clinical trials for FGFR3 GENE SHORT VARIANTS explained in plain language.

Never miss a new study

Get alerted when new FGFR3 GENE SHORT VARIANTS trials appear

Sign up with your email to follow new studies for FGFR3 GENE SHORT VARIANTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New targeted drug shows promise for Hard-to-Treat cancers with FGFR mutations

Disease control Ongoing

This study tests a new drug called CGT4859 in people with bile duct cancer (cholangiocarcinoma) or other advanced solid tumors that have specific genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About …

Matched conditions: FGFR3 GENE SHORT VARIANTS

Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control

Last updated May 15, 2026 11:53 UTC

FGFR3 GENE SHORT VARIANTS

Get alerted when new FGFR3 GENE SHORT VARIANTS trials appear

New targeted drug shows promise for Hard-to-Treat cancers with FGFR mutations